Viscosupplementation Market Size

  • Report ID: 4381
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Viscosupplementation Market Size

Viscosupplementation Market size was over USD 4.78 billion in 2024 and is set to reach USD 14.96 billion by the end of 2037, growing at around 9.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of viscosupplementation is assessed at USD 5.13 billion. The growth of the market can be attributed to the escalating prevalence of osteoarthritis across the globe, owing to the shift of the population towards unhealthy lifestyles and consumption of processed food which in turn is expected to foster arthritis cases. Arthritis is a condition in which people get swelling or inflammation in joints and more than 100 conditions are described by arthritis that affects tissues around joints and other tissues connected to it. For instance, in 2019, there were approximately 526.90 million osteoarthritides (OA) occurrences worldwide. The healthcare provider injects hyaluronic acid into the joints during viscosupplementation treatment to reduce swelling and any sort of pain in the joints.

Osteoarthritis patients have lower levels of hyaluronic acid in their joints, which causes pain. Therefore, a proper infusion of hyaluronic acid delivers optimum results in the elasticity of knee cartilage. It was observed in clinical research that, hyaluronic acid (HA) is a widely known high molecular weight natural glycosaminoglycan consisting of repeating units of D-glucuronic acid and N-acetylglucosamine disaccharide linked by biopolymer B-(1-4) and B-(1-3) glycosides. HA promotes cartilage matrix synthesis and improves cartilage elasticity and humidity. Several orthotic devices, casts, and splints are also utilized to treat the condition of osteoarthritis. It also prevents chondrocyte apoptosis and increases proteoglycan synthesis. As a result, HA is essential for avoiding cartilage erosion and reducing synovial inflammation. In OA patients, the rate of depolymerization and clearance of endogenous HA in joints is higher than normal, which lessens not only the density and molecular weight of HA but also the elastic viscosity of the synovial fluid.


Viscosupplementation-Market
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4381
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of viscosupplementation is assessed at USD 5.13 billion.

The viscosupplementation market size was over USD 4.78 billion in 2024 and is set to reach USD 14.96 billion by the end of 2037, growing at around 9.1% CAGR during the forecast period i.e., between 2025-2037. Increasing geriatric population and high prevalence of obesity will boost the market growth.

North America industry is projected to account for majority revenue share by of 2037, owing to increasing geriatric population, escalating preference for short treatment schedules, and the growing occurrence of osteoarthritis in the region.

The major players in the market include Sanofi S.A., Anika Therapeutics, Inc., Seikagaku Corporation, Smith & Nephew PLC, Lifecore Biomedical, Inc., LG Chem Life Sciences Innovation Center, Inc., Fidia Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co., Ltd., OrthogenRx, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample